Brought to you by 
Heptares helps Takeda discover new CNS compounds
22 Feb 2023
Executive Summary
GPCR company Heptares Therapeutics Ltd. will use its proprietary platforms to discover new CNS drug candidates for Takeda Pharmaceutical Co. Ltd.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Heptares helps Takeda discover new CNS compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice